Company Alcon London S.E.
Stocks
CH0432492467
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Cboe BZX
11:12:33 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 69.30 USD | +18.89% |
|
0.00% | - |
| 09-04 | Alert incorrectly tagged to Omega Interactive Technologies withdrawn | RE |
| 09-03 | Alcon Launches UNITY M, A Premium Ophthalmic Microscope Delivering Precise Control | CI |
Business description: Alcon
- ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors;
- vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.).
At the end of 2025, the group operated 17 production sites worldwide.
Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Sales by Activity: Alcon
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Surgical | 4.7B | 5.04B | 5.31B | 5.53B | 5.75B |
Vision Care | 3.59B | 3.67B | 4.14B | 4.38B | 4.65B |
Geographical breakdown of sales: Alcon
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 3.65B | 3.9B | 4.31B | 4.51B | 4.66B |
Rest of World | 3.4B | 3.66B | 3.88B | 4.13B | 4.41B |
Japan | 621M | 568M | 583M | 554M | 609M |
China | 486M | 474M | 526M | 560M | 570M |
Switzerland | 60M | 59M | 64M | 79M | 71M |
Executive Committee: Alcon
| Manager | Title | Age | Since |
|---|---|---|---|
David Endicott
CEO | Chief Executive Officer | 60 | 2018-06-30 |
| Director of Finance/CFO | 58 | 2019-04-07 | |
Patrick Collier
CTO | Chief Tech/Sci/R&D Officer | - | 2024-12-31 |
Muru Murugappan
CTO | Chief Tech/Sci/R&D Officer | - | 2024-07-31 |
Ian Bell
COO | Chief Operating Officer | 56 | 2023-12-31 |
Composition of the Board of Directors: Alcon
| Director | Title | Age | Since |
|---|---|---|---|
David Endicott
BRD | Director/Board Member | 60 | - |
F. Ball
CHM | Chairman | 70 | 2018-06-30 |
Lynn Bleil
BRD | Director/Board Member | 63 | 2019-01-31 |
Arthur Cummings
BRD | Director/Board Member | 63 | 2018-12-31 |
| Director/Board Member | 67 | 2018-12-31 | |
D. Grossman
BRD | Director/Board Member | 66 | 2019-03-31 |
Karen May
BRD | Director/Board Member | 68 | 2018-12-31 |
Ines Pöschel
BRD | Director/Board Member | 58 | 2018-12-31 |
Dieter Spälti
BRD | Director/Board Member | 65 | 2018-12-31 |
Deborah DiSanzo
BRD | Director/Board Member | 66 | 2025-08-31 |
Holdings: Alcon
| Name | Stocks | % | Valuation |
|---|---|---|---|
OCUMENSION THERAPEUTICS 16.64% | 139,159,664 | 16.64% | 92 M $ |
Company details: Alcon
Group companies: Alcon
| Name | Category and Sector |
|---|---|
Alcon Laboratories (India) Pvt Ltd.
 Alcon Laboratories (India) Pvt Ltd. Medical DistributorsDistribution Services Supplies eye care devices |
Medical Distributors
|
Alcon Finance BV
 Alcon Finance BV Finance/Rental/LeasingFinance Functions as a financing subsidiary/special purpose entity |
Finance/Rental/Leasing
|
Alcon Management SA | |
Alcon Finance Corp.
 Alcon Finance Corp. Finance/Rental/LeasingFinance Functions as a financing subsidiary/special purpose entity |
Finance/Rental/Leasing
|
Alcon Singapore Manufacturing Pte Ltd.
 Alcon Singapore Manufacturing Pte Ltd. Pharmaceuticals: MajorHealth Technology Engages in chemical preparations |
Pharmaceuticals: Major
|
Glasses, Spectacles & Contact Lenses
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.91% | -6.05% | -42.79% | -13.52% | 79.39B | |
| -1.63% | -4.15% | -11.58% | -24.08% | 34.04B | |
| -2.15% | -2.26% | -1.56% | -22.61% | 13.57B | |
| +1.13% | +4.82% | - | - | 12.65B | |
| +2.57% | -1.92% | -4.73% | +625.95% | 2.64B | |
| +0.64% | -0.36% | -38.44% | -57.43% | 1.46B | |
| -0.54% | +7.13% | - | - | 968M | |
| -0.92% | -5.88% | +16.41% | +1.48% | 924M | |
| -0.88% | -1.84% | -36.50% | -20.69% | 887M | |
| Average | -0.10% | -1.27% | -17.03% | +69.87% | 16.28B | |
| Weighted average by Cap. | +0.04% | -4.56% | -29.33% | -4.86% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ALC Stock
- Stock
- Company Alcon
Select your edition
All financial news and data tailored to specific country editions
